NexImmune Inc is a biotechnology business based in the US. NexImmune Inc shares (NEXI) are listed on the PINK and all prices are listed in US Dollars. Its last market close was $0.00 – the same closing value as a week prior. NexImmune Inc employs 6 staff and has a market cap (total outstanding shares value) of 0.00.
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $0.00 |
|---|---|
| 52-week range | $0.00 - $3.93 |
| 50-day moving average | $0.01 |
| 200-day moving average | $0.27 |
| Wall St. target price | $2.00 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-18.51 |
Historical closes compared with the close of $0.0001 from 2025-05-02
| 1 week (2025-04-29) | 0.0001 |
|---|---|
| 1 month (2025-04-07) | 0.0001 |
| 3 months (2025-02-07) | -99.91% |
| 6 months (2024-11-07) | -99.96% |
| 1 year (2024-05-07) | -100.00% |
|---|---|
| 2 years (2023-05-05) | -100.00% |
| 3 years (2022-05-06) | 74 |
| 5 years (2020-05-03) | N/A |
| Gross profit TTM | $0 |
|---|---|
| Return on assets TTM | -72.7% |
| Return on equity TTM | -232.97% |
| Profit margin | 0% |
| Book value | $0.50 |
| Market Capitalization | $139 |
TTM: trailing 12 months
We're not expecting NexImmune Inc to pay a dividend over the next 12 months.
You may also wish to consider:
NexImmune Inc's shares were split on a 1:25 basis on 18 October 2023 . So if you had owned 25 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your NexImmune Inc shares – just the quantity. However, indirectly, the new 2400% higher share price could have impacted the market appetite for NexImmune Inc shares which in turn could have impacted NexImmune Inc's share price.
Over the last 12 months, NexImmune Inc's shares have ranged in value from as little as $0.0001 up to $3.93. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (PINK average) beta is 1, while NexImmune Inc's is 2.022. This would suggest that NexImmune Inc's shares are significantly more volatile than the average for this exchange and represent a higher risk.
To put NexImmune Inc's beta into context you can compare it against those of similar companies.
NexImmune, Inc. , a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases in the United States. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a nanoparticle technology platform. The company's product candidates include NEXI-001, an allogeneic cell therapy, which is in Phase I/II clinical trials for the treatment of patients with acute myeloid leukemia; NEXI-002, an autologous cell therapy that is in Phase I/II clinical trials for the treatment of patients with relapsed and/or refractory in multiple myeloma; and NEXI-003, a product candidate targeted against HPV related cancers, which is in Phase I/II clinical trials. It provides NEXI-004 which is in preclinical stage for EBV related diseases; and NEXI005 designs for patient with specific targets for solid tumors. NexImmune, Inc. was incorporated in 2011 and is headquartered in Gaithersburg, Maryland.
Some of the best paper trading apps to practice stock trading with fake money include Interactive Brokers, eToro, Charles Schwab and more.
These are the stocks to buy when you don’t have much to spend.
These are the best day trading apps, according to Finder’s comprehensive analysis.
Explore the best bonuses for opening a new brokerage account.
Some of the best stock trading apps for beginners include SoFi, Robinhood, Public, Stash, Opto and more. Compare your options here.
Want to buy and sell international stocks? Here are the top brokers to help you trade global markets.
These are the best discount brokers of 2025 according to Finder’s comprehensive review.
Compare the 7 best stock picking services, according to Finder’s analysis, and learn how to choose the best option for your needs.
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .